906352-61-2 Usage
Uses
Used in Pharmaceutical Research:
2-[4-(chloromethyl)phenyl]-1,3-thiazole is utilized as a potential drug candidate in pharmaceutical research for its therapeutic properties. It is being explored for its efficacy as an antibacterial and antifungal agent, indicating its potential in combating various microbial infections.
Used in Materials Science:
In the field of materials science, 2-[4-(chloromethyl)phenyl]-1,3-thiazole is studied for its potential applications in the development of organic electronic devices and sensors. Its unique structure and properties make it a candidate for enhancing the performance of these technologies.
Used in Organic Electronic Devices:
2-[4-(chloromethyl)phenyl]-1,3-thiazole is used as a component in the development of organic electronic devices due to its electronic properties, which can contribute to the improvement of device performance and functionality.
Used in Sensor Technology:
2-[4-(chloromethyl)phenyl]-1,3-thiazole is also considered for use in sensor technology, where its chemical reactivity and electronic characteristics can be leveraged to create sensitive and selective detection mechanisms for various analytes.
Check Digit Verification of cas no
The CAS Registry Mumber 906352-61-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,6,3,5 and 2 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 906352-61:
(8*9)+(7*0)+(6*6)+(5*3)+(4*5)+(3*2)+(2*6)+(1*1)=162
162 % 10 = 2
So 906352-61-2 is a valid CAS Registry Number.
906352-61-2Relevant academic research and scientific papers
Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility
Ang, Chee Wei,Tan, Lendl,Sykes, Melissa L.,Abugharbiyeh, Neda,Debnath, Anjan,Reid, Janet C.,West, Nicholas P.,Avery, Vicky M.,Cooper, Matthew A.,Blaskovich, Mark A. T.
, p. 15726 - 15751 (2020/12/02)
Following the approval of delamanid and pretomanid as new drugs to treat drug-resistant tuberculosis, there is now a renewed interest in bicyclic nitroimidazole scaffolds as a source of therapeutics against infectious diseases. We recently described a nitroimidazopyrazinone bicyclic subclass with promising antitubercular and antiparasitic activity, prompting additional efforts to generate analogs with improved solubility and enhanced potency. The key pendant aryl substituent was modified by (i) introducing polar functionality to the methylene linker, (ii) replacing the terminal phenyl group with less lipophilic heterocycles, or (iii) generating extended biaryl side chains. Improved antitubercular and antitrypanosomal activity was observed with the biaryl side chains, with most analogs achieved 2- to 175-fold higher activity than the monoaryl parent compounds, with encouraging improvements in solubility when pyridyl groups were incorporated. This study has contributed to understanding the existing structure-activity relationship (SAR) of the nitroimidazopyrazinone scaffold against a panel of disease-causing organisms to support future lead optimization.
